Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: Treatment with meclizine

Abstract

Withdrawal symptoms experienced after removal of a transdermal scopolamine patch were successfully treated with oral meclizine.

Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study

“…8 Transdermal scopolamine, another anticholinergic, effectively prevented bladder contractions after open prostatectomy, 12 but has been associated with a decreased salivary flow rate and mouth dryness. 13 Urgency to urinate and increased frequency of urination are symptoms of CRBD, which are similar to those of an overactive bladder. CRBD and overactive bladder result from involuntary contractions of the bladder detrusor muscle mediated by muscarinic receptors and, therefore, antimuscarinic therapy that suppresses involuntary bladder contractions has been used to treat overactive bladder.…”

Hyoscine patch withdrawal syndrome in a returned traveller

“…Hyoscine patch withdrawal is a recognised phenomenon internationally. [1][2][3] These patches are not available in Australia and we are unaware of previous similar cases domestically.…”

Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse

“…Some case reports have revealed hallucinogenic effects of scopolamine, largely from patients of different age groups in whom hallucinations unexpectedly followed peripheral administrations (transdermal patch or eye drops) of scopolamine (Warburton et al, 1985;Sennhauser and Schwarz, 1986). A sparse amount of literature predicts that scopolamine could be addictive and it is likely to cause CNS effects upon withdrawal (Luetje and Wooten, 1996;Patel and Ezzo, 2009), but its recreational or predatory use has not been convincingly identified (King et al, 2014). On the other hand, scopolamine might have a beneficial effect in opioid and cocaine addiction (Gambelunghe et al, 2014;Liu et al, 2013).…”